Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells by Rütti, S et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Low and high-density lipoproteins modulate function, apoptosis
and proliferation of primary human and murine pancreatic beta
cells
Rütti, S; Ehses, J A; Sibler, R A; Prazak, R; Rohrer, L; Georgopoulos, S; Meier, D T;
Niclauss, N; Berney, T; Donath, M Y; von Eckardstein, A
Rütti, S; Ehses, J A; Sibler, R A; Prazak, R; Rohrer, L; Georgopoulos, S; Meier, D T; Niclauss, N; Berney, T;
Donath, M Y; von Eckardstein, A (2009). Low and high-density lipoproteins modulate function, apoptosis and
proliferation of primary human and murine pancreatic beta cells. Endocrinology:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Endocrinology 2009, :Epub ahead of print.
Rütti, S; Ehses, J A; Sibler, R A; Prazak, R; Rohrer, L; Georgopoulos, S; Meier, D T; Niclauss, N; Berney, T;
Donath, M Y; von Eckardstein, A (2009). Low and high-density lipoproteins modulate function, apoptosis and
proliferation of primary human and murine pancreatic beta cells. Endocrinology:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Endocrinology 2009, :Epub ahead of print.
Low and high-density lipoproteins modulate function, apoptosis
and proliferation of primary human and murine pancreatic beta
cells
Abstract
A low high-density lipoprotein (HDL) plasma concentration and the abundance of small dense
low-density lipoproteins (LDL) are risk factors for developing type 2 diabetes. We therefore
investigated whether HDL and LDL play a role in the regulation of pancreatic islet cell apoptosis,
proliferation and secretory function. Isolated mouse and human islets were exposed to plasma
lipoproteins of healthy human donors. In murine and human beta-cells LDL decreased both proliferation
and maximal glucose-stimulated insulin secretion. The comparative analysis of beta-cells from wild type
and LDL receptor deficient mice revealed that the inhibitory effect of LDL on insulin secretion but not
on proliferation requires the LDL receptor. HDL was found to modulate the survival of both human and
murine islets by decreasing basal as well as IL-1beta and glucose induced apoptosis. IL-1beta induced
beta-cell apoptosis was also inhibited in the presence of either the delipidated protein or the
deproteinated lipid moieties of HDL, apolipoprotein A1 (the main protein component of HDL) or
sphingosine-1-phosphate (a bioactive sphingolipid mostly carried by HDL). In murine beta-cells, the
protective effect of HDL against IL-1beta induced apoptosis was also observed in the absence of the
HDL receptor scavenger receptor class B type 1 (SRB1). Our data show that both LDL and HDL affect
function or survival of beta-cells and raise the question whether dyslipidemia contributes to beta-cell
failure and hence the manifestation and progression of type 2 diabetes mellitus.
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A low high-density lipoprotein (HDL) plasma concentration and the abundance of small dense low-35 
density lipoproteins (LDL) are risk factors for developing type 2 diabetes. We therefore investigated 36 
whether HDL and LDL play a role in the regulation of pancreatic islet cell apoptosis, proliferation and 37 
secretory function. Isolated mouse and human islets were exposed to plasma lipoproteins of healthy 38 
human donors. In murine and human β-cells LDL decreased both proliferation and maximal glucose-39 
stimulated insulin secretion. The comparative analysis of β-cells from wild type and LDL receptor 40 
deficient mice revealed that the inhibitory effect of LDL on insulin secretion but not on proliferation 41 
requires the LDL receptor. HDL was found to modulate the survival of both human and murine islets 42 
by decreasing basal as well as IL-1β and glucose induced apoptosis. IL-1β induced β-cell apoptosis 43 
was also inhibited in the presence of either the delipidated protein or the deproteinated lipid moieties 44 
of HDL, apolipoprotein A1 (the main protein component of HDL) or sphingosine-1-phosphate (a 45 
bioactive sphingolipid mostly carried by HDL). In murine β-cells, the protective effect of HDL against 46 
IL-1β induced apoptosis was also observed in the absence of the HDL receptor scavenger receptor 47 
class B type 1 (SRB1). Our data show that both LDL and HDL affect function or survival of β-cells 48 
and raise the question whether dyslipidemia contributes to β-cell failure and hence the manifestation 49 
and progression of type 2 diabetes mellitus. 50 
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INTRODUCTION 51 
The development of type 2 diabetes is characterized by a decrease in the functional β-cell mass that 52 
can no longer compensate for insulin resistance (1, 2, 3). Patients with type 2 diabetes display, along 53 
with hyperglycaemia, elevated circulating levels of free fatty acids, triglycerides and small dense LDL 54 
particles as well as low plasma levels of HDL cholesterol and its major protein component 55 
apolipoprotein A1 (ApoA1) (4). Even more so, low HDL cholesterol, hypertriglyceridemia and small 56 
dense LDL often precede the manifestation of type 2 diabetes and epidemiological studies have shown 57 
that low HDL cholesterol is an independent risk factor for developing type 2 diabetes (5). Recent data 58 
in rodent β-cells have indicated a role for lipoproteins in the regulation of islet cell survival and insulin 59 
synthesis suggesting a causal or modulatory role of lipoproteins in the precipitation of type 2 diabetes 60 
(6, 7). 61 
In fact primary murine β-cells as well β-cell lines such as βTC3 were found to express various 62 
lipoprotein receptors including members of the LDL receptor gene family and the scavenger receptor 63 
B gene family. In addition both LDL and HDL were found to modulate the survival of these cells. 64 
High concentrations of native LDL as well as oxidatively modified LDL decreased the proliferation 65 
and increased apoptosis of β-cells (6-8). In addition mice with a conditional knock-out of the ATP 66 
binding cassette transporter A1 (ABCA1) in pancreatic β-cells were found to be glucose intolerant due 67 
to cholesterol overloading of β-cells and insufficient insulin secretion (9). 68 
This study was undertaken to examine the effects of LDL and HDL on the survival, proliferation and 69 
function of primary human and mouse islet cells and to unravel the lipoprotein components and 70 
lipoprotein receptors which mediate any of these effects. We found that prolonged exposure to LDL 71 
impairs insulin secretion in a possibly LDL-receptor-dependent manner, and decreases human and 72 
mouse islet cell proliferation independently of the LDL receptor. To unravel any protective effects of 73 
HDL we challenged islet cells with glucose or IL-1β as known diabetogenic factors (10, 11). Under 74 
this condition entire HDL particles as well as isolated ApoA1 and sphingosine-1-phosphate (S1P), a 75 
bioactive lipid mostly carried by HDL (12), were found to mediate these protective effects. The anti-76 
apoptotic effect of HDL did not require expression of the scavenger receptor B1 (SRB1). 77 
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MATERIALS AND METHODS 78 
Isolation of HDL, LDL and HDL protein and lipid moieties. Blood was collected from healthy 79 
donors. Plasma LDL and HDL fractions were isolated by sequential ultracentrifugation (LDL: 1.006 < 80 
LDL density < 1.063; HDL: 1.063 < HDL density < 1.21), dialyzed against LDL-buffer (NaCl 1.5 M, 81 
EDTA 3 mM, pH 7.4) and finally filter sterilized using a 0.22 μm microfilter (13). Cholesterol 82 
concentrations of the isolated lipoproteins were measured using the CHOD-PAP method on a Cobas 83 
Modular autoanalyser (Roche diagnostics, Rotkreuz, Switzerland) and used for the calibration of 84 
lipoprotein amounts given to the cells. In average 1 mM LDL cholesterol (LDL-C) and HDL-85 
cholesterol (HDL-C) correspond to 0.36 and 1.5 mg/ml protein, respectively. The purity of the 86 
lipoprotein preparation was verified by apolipoprotein composition analysis in a 10% sodium dodecyl 87 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to exclude contaminations with LDL or 88 
albumin in the HDL fraction and to exclude contamination with HDL or albumin in the LDL fraction. 89 
HDL and LDL from different donors have never been pooled and were always used rapidly after 90 
isolation to prevent any modification or degradation. The lipid-free protein and protein free lipid 91 
moieties of HDL were extracted and purified as described previously (14, 15). The protein free lipid 92 
moiety was bound to 1% fatty acid free BSA (Sigma-Aldrich, USA) prior to incubation with the islet 93 
cells. 1% BSA did not influence mouse islet cell survival. 94 
Islet isolation and culture. Human islets were isolated from pancreata of organ donors at the 95 
University of Geneva Medical Center. Human islets were cultured in CMRL-1066 medium containing 96 
5 mmol/l glucose, 100 units/ml penicillin, 100 μg/ml streptomycin and 10% FCS (Invitrogen, Basel, 97 
Switzerland). Islets from 20 different donors (11 males, 9 females) were used for this study (age 98 
average: 49; BMI average: 27). Mouse islets were isolated from C57BL/6J mice, LDL receptor 99 
deficient (LDLR -/-) mice (Jackson Laboratory, USA), and scavenger receptor B1 deficient (SRB1 -/-) 100 
mice (16) by collagenase digestion (Worthington Biochemical Corporation, Lakewood, USA) and 101 
separated from the exocrine tissue by density gradient (Histopaque-1119, Sigma-Aldrich, USA) as 102 
previously described (17). Islets were further handpicked prior to plating for higher purity. Mouse 103 
islets were cultured in RPMI-1640 medium containing 11 mmol/l glucose, 40 μg/ml gentamycin, 100 104 
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units/ml penicillin, 100 μg/ml streptomycin and 10% FCS (Invitrogen, Basel, Switzerland). Islets were 105 
cultured on extracellular matrix-coated plates (20 islets/plate) derived from bovine corneal endothelial 106 
cells (Novamed, Jerusalem, Israel). The islets cultured on extracellular matrix-coated plates were left 107 
in islet media for 48h to adhere and spread before initiation of the experiments. To obtain single islet 108 
cells, freshly isolated mouse islets were trypsinized and mechanically dispersed as previously 109 
described (18). The single cells were cultured on extracellular matrix-coated plates. Islets were treated 110 
with glucose, IL-1beta (R&D, Minneapolis, USA), HDL, LDL, human apolipoprotein A1 111 
(Calbiochem, San Diego, USA) or sphingosine-1-phosphate (Avanti polar lipids, Alabaster, USA) at 112 
concentrations reported in the results section. Sphingosine-1-phosphate was added to the cells coupled 113 
to 1% fatty acid free BSA (Sigma-Aldrich, USA). 114 
Insulin secretion. For acute insulin release in response to glucose, islets (20 islets/plate) were washed 115 
and incubated in Krebs-Ringer buffer containing 2.8 or 16.7 mmol/l glucose and 0.5% BSA for 1h. 116 
Islet insulin was extracted with 0.18 mol/l HCl in 70% ethanol for determination of insulin content. 117 
Secreted insulin and insulin content was assayed by radioimmunoassay (CIS Biointernational, Gif-sur-118 
Yvette, France) (17). For each condition in each individual experiment, 3 plates with 20 islets each 119 
were treated. Each n represents a different human islet donor or different mouse islet isolation and a 120 
different plasma donor. 121 
Proliferation and apoptosis of islet cells. For human islet cell proliferation studies, a monoclonal 122 
antibody against the human Ki-67 antigen (Monoclonal mouse anti Ki-67 prediluted, incubation: 1 123 
hour at room temperature, Zymed laboratories, San Fransisco, USA) was used (secondary antibody: 124 
Histostain Plus Kit, Zymed laboratories, San Fransisco, USA). For mouse islet cell proliferation 125 
studies, BrdU was added to the mouse islets at the start of the treatment. The incorporated BrdU was 126 
detected with an anti-Brdu antibody (dilution: 1/10, incubation: 30 minutes at 37°C, Roche, Basel, 127 
Switzerland; secondary antibody: donkey anti mouse Cy3 (715-165-150), dilution :1/50, incubation: 128 
30 minutes at 37°C, Jackson Immunoresearch, Baltimore, USA). The free 3’-OH strand breaks 129 
resulting from DNA degradation were detected by the terminal deoxynucleotidyl-transferase-mediated 130 
dUTP nick-end labelling (TUNEL) technique according to the manufacturer’s instructions (In Situ 131 
Cell Death Detection Kit, Roche, Basel, Switzerland). For mouse islet single cell proliferation studies, 132 
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BrdU was added to the single cells at the start of the treatment. The incorporated BrdU was detected 133 
with an anti-Brdu antibody (dilution: 1/10, incubation: 30 minutes at 37°C, Roche, Basel, Switzerland; 134 
secondary antibody: donkey anti mouse Cy3 (715-165-150), dilution: 1/50, incubation: 30 minutes at 135 
37°C, Jackson Immunoresearch, Baltimore, USA) and the single cells were co-stained with a guinea 136 
pig anti-insulin antibody (dilution :1/50, incubation: 30 minutes at 37°C, Dako, Glostrup, Danemark; 137 
secondary antibody: donkey anti-guinea pig FITC (706-096-148), dilution: 1/50, incubation: 30 138 
minutes at 37°C, Jackson Immunoresearch, Baltimore, USA). The numbers of apoptotic or 139 
proliferative cells were determined by careful counting with a fluorescent microscope (Axioplan 2, 140 
Zeiss, Germany) as previously described (18). For each condition in each individual experiment 50 141 
islets were analysed. Each n represents a different human islet donor or different mouse islet isolation 142 
and a different plasma donor. 143 
Confocal imaging of β-cell apoptosis. Mouse islets were co-stained for apoptosis (TUNEL, as 144 
described above), insulin (dilution: 1/50, incubation: 30 minutes at 37°C, Dako, Glostrup, Danemark; 145 
secondary antibody: donkey anti-guinea pig Cy5 (706-175-148), dilution: 1/100, incubation: 30 146 
minutes at 37°C, Jackson Immunoresearch, Baltimore, USA) and nuclei (4’,6-diamidino-2-147 
phenylindole, DAPI, dilution 1/1000, incubation: 30 minutes at 37°C). Multiple labelling 148 
immunofluorescence images of mouse islets were captured using a scanning confocal head coupled to 149 
an upright microscope (TCS SP2, Leica, Wetzlar, Germany) with UV light and Ar-Kr laser utilizing 150 
358 nm, 488 nm and 647 nm excitation and 63x/1.40 oil PlanApo objective lens. For each islet series, 151 
eight pictures, corresponding to eight different z planes were acquired with Leica software and 152 
merged. The series allowed the determination of the number of apoptotic β-cells and non β-cells for 153 
each islet. For each condition in each individual experiment 30 to 40 islets were analysed. Each n 154 
represents a different human islet donor or different mouse islet isolation and a different plasma donor. 155 
RNA extraction and real-time PCR. Total mouse islet RNA was extracted from 100 islets plated on 156 
extracellular matrix-coated culture dishes with a total RNA extraction kit (Nucleospin RNAII, 157 
Marchery Nagel, Düren, Germany) and reverse transcribed with random hexamers as previously 158 
published (19). Commercially available mouse primers to 18s rRNA, Fas, FLIP, iNOS, SOCS3 and 159 
Bcl2 were purchased and assayed according to the manufacturer’s protocol using the ABI 7000 system 160 
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(Applied Biosystems, Foster City, USA). Changes in mRNA expression were calculated using the 161 
difference of Ct (cycle threshold) values. 162 
Statistical analysis. Data are expressed as means ± SEM, with the number of individual experiments 163 
presented in the figure legends. Data were normalized with the control set to 1. All data were tested for 164 
normality and analysed with PRISM (GraphPad, San Diego, USA). Significance was tested using 165 
Student’s t test and ANOVA with Bonferonni’s post hoc test for multiple comparison analysis. 166 
Significance was set as p<0.05. 167 
RESULTS 168 
LDL decreases proliferation and function of murine and human β-cells. Human and mouse islets 169 
were cultured on extracellular matrix-coated plates for 4 days in the presence of increasing 170 
concentrations of LDL-C (LDL cholesterol). Already LDL-C concentrations as low as 0.8 mM and 1 171 
mM (as defined by cholesterol concentration) decreased the proliferation of mouse and human islet 172 
cells by 50% and 70%, respectively. Higher concentrations did not aggravate the antiproliferative 173 
effect of LDL in either murine or human islets (Fig. 1A and B). Furthermore, as determined by 174 
counting of single islet cells co-stained for insulin and BrdU (Fig. 1G), the decrease in islet cell 175 
proliferation was found to occur in β-cells. Already after 2 days incubation, 3.1 mM LDL-C 176 
deacreased mouse islet cells proliferation (Fig. 1H). However, the anti-proliferative effect of LDL was 177 
milder after 2 days than after 4 days incubation. LDL did not cause apoptosis of mouse or human islet 178 
cells (Fig. 1C and D). To rule out that LDL particle modification (oxidation) during the incubation 179 
time was responsible for the observed effect, the experiments were repeated with media and LDL 180 
changed and added fresh every day during the 4 days culture period. Under these conditions LDL still 181 
decreased basal mouse islet cell proliferation by 50% (control = 5.6±1.8 and 3.1 mM LDL = 2.5±0.7* 182 
BrdU positive cells/islet, n=6, p<0.05). Similarly, in the presence of a cocktail of anti-oxidants 183 
(vitamin A 1 μM, vitamin E 0.5 μM, DTT 10 μM) LDL also decreased basal mouse islet cell 184 
proliferation during 4 days of incubation (control = 0.6±0.12 and 3.1 mM LDL = 0.09±0.04* BrdU 185 
positive cells/islet, n=3, p<0.05). Furthermore, in human and mouse islets 3.1 mM and 6.2 mM LDL-186 
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C decreased maximal glucose-stimulated insulin secretion (Fig. 1E and F). Based on the results 187 
described here, we used LDL at physiological concentrations of 3.1 mM, for subsequent experiments. 188 
The LDL receptor mediates the inhibitory effect of LDL on insulin secretion but not its 189 
inhibitory effect on islet cell proliferation. To investigate whether the LDL receptor mediates the 190 
inhibitory effects of LDL on β-cell proliferation and insulin secretion, islets isolated from LDLR -/- 191 
and wild type mice were exposed for 4 days to LDL. LDL decreased basal proliferation, independently 192 
of LDL receptor expression (Fig. 2A and B). By contrast the trend towards an impairment of maximal 193 
glucose-stimulated insulin secretion by LDL was observed in wild type islets but not in islets of LDLR 194 
-/- mice (Fig. 2C, D and E). In both strains, the presence of LDL did not affect insulin content (LDLR 195 
+/+: control = 188±43 μg/l per 20 islets, LDL = 181±81 μg/l per 20 islets, n=3, n.s.; LDLR -/-: control 196 
= 279±93 μg/l per 20 islets, LDL = 134±38 μg/l per 20 islets, n=3, n.s.) or insulin mRNA expression 197 
(LDLR +/+: control = reference = 1; LDL = 0.9±0.4, n=2; LDLR -/-: control = reference = 1, LDL = 198 
1.2±0.5, n=2). 199 
HDL decreases basal apoptosis of islet cells. Human and mouse islets were cultured on extracellular 200 
matrix-coated plates for 4 days in the presence of various concentrations of HDL. Exposure to 0.8 mM 201 
HDL-C (as defined by cholesterol concentration) induced a 30% decrease in mouse islet cell apoptosis 202 
(Fig. 3C), without affecting proliferation (Fig 3A) or glucose-stimulated insulin secretion (Fig. 3E). 203 
Lower HDL concentrations did not affect function, proliferation, or apoptosis of mouse islets. 204 
Similarly, exposure of human islets to 0.5 or 1 mM HDL-C induced a 30 to 60% decrease in islet cell 205 
apoptosis (Fig. 3D) and did not affect proliferation or glucose-stimulated insulin secretion (Fig. 3B 206 
and F). Based on the dose-response results, all subsequent experiments on mouse and human islets 207 
were performed with HDL at concentrations of 0.8 mM and 1 mM HDL-C, respectively.  208 
HDL protects β-cells against glucose or IL-1β induced apoptosis. To further assess the anti-209 
apoptotic effect of HDL, human and mouse islets were cultured on extracellular matrix-coated plates 210 
for 4 days in the presence of elevated glucose concentrations and 0.8 mM (mouse) or 1 mM (human) 211 
HDL-C. As previously reported (20), glucose induced a 2-fold increase in mouse and human islet cells 212 
apoptosis (Fig. 4A and B). Interestingly, HDL was able to prevent the apoptosis induced by the 213 
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presence of elevated glucose concentrations in both human and mouse islets. Moreover, HDL 214 
protected mouse islet cells from IL-1β induced apoptosis after 2 days in culture (Fig. 4C). To 215 
determine which islet cell type is protected by HDL against IL-1β induced apoptosis, mouse islets 216 
were exposed for 2 days to IL-1β alone or with IL-1β and HDL to be then analysed for apoptosis with 217 
confocal microscopy. By colocalization, this method allowed us to determine if the apoptotic cells 218 
were insulin positive (β-cells) or not (non-β-cells). Indeed HDL protected mouse β-cells from IL-1β 219 
induced apoptosis, with no effect on non β-cells (Fig. 4D, E and F). 220 
Beta-cell protection against IL-1β induced apoptosis is independent of SRB1. In an attempt to 221 
uncover which receptor is involved in the protection of β-cells by HDL against IL-1β induced 222 
apoptosis, islets obtained from SRB1 -/- or wild type mice were exposed for 2 days to IL-1β alone or 223 
in the presence of HDL. SRB1 is known to be expressed on mouse islets (6). The islets were analysed 224 
for apoptosis by confocal microscopy, allowing the identification of apoptotic β-cells. HDL protected 225 
β-cells from IL-1β induced apoptosis in wild type and SRB1 -/- islets to the same degree, although the 226 
anti-apoptotic effect was not statistically significant in the latter (Fig. 5A and B). 227 
Both ApoA1 and S1P protect islet cells from IL-1β and glucose induced apoptosis. To determine 228 
which HDL component is mediating the protective effect against IL-1β and glucose induced apoptosis, 229 
HDL was delipidated. Mouse islets were treated with either the lipid-free protein moiety (pHDL) or 230 
the protein-free lipid moiety (lHDL) of HDL. Similarly to HDL, the lipid-free protein moiety of HDL 231 
protected mouse islet cells from glucose induced apoptosis (Fig. 5C). Likewise 20 μg/ml purified 232 
ApoA1 which constitutes the major protein in HDL protected mouse islets from glucose induced 233 
apoptosis (Fig. 5D). In addition, 20 μg/ml lipid free ApoA1 also inhibited the apoptosis of mouse 234 
islets induced by IL-1β (Fig. 5E). Surprisingly, the lipid moiety of HDL also protected islets from IL-235 
1β induced apoptosis after 2 days (Fig 5F). 1 μM sphingosine-1-phosphate (S1P), a bioactive 236 
sphingolipid carried by HDL, also protected mouse islet cells from IL-1β induced apoptosis (Fig 5G). 237 
Therefore, both the protein and lipid moieties of HDL displayed anti-apoptotic effects on islets. 238 
HDL modulates iNOS, Fas and FLIP mRNA expression. Finally, we investigated the mechanisms 239 
underlying the anti-apoptotic effect of HDL in mouse islets. Incubation of mouse islets with 0.8 mM 240 
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HDL-C for 2 days strongly decreased basal mRNA expression of inducible nitric oxide synthase 241 
(iNOS) (Fig 6A) as well as the extent of IL-1β induced iNOS mRNA expression (Fig 6B). In addition 242 
after 4 days incubation HDL was found to modulate the expression of Fas and FLIP, two molecules 243 
involved in the extrinsic apoptosis pathway. Indeed, HDL down-regulated the expression of the death 244 
receptor Fas by 30% and up-regulated FLIP, an inhibitory protein of the Fas pathway by 50% (Fig 6C 245 
and D). By contrast HDL did not modulate the expression of SOCS3 and Bcl2, two other molecules 246 
involved in the apoptotic process (Fig. 6E and F). 247 
DISCUSSION 248 
In this study of primary mouse and human islets we found that LDL exerts potentially diabetogenic 249 
effects by decreasing both maximal insulin secretion and proliferation of β-cells, whereas HDL exerts 250 
potentially anti-diabetogenic effects by inhibiting β-cell apoptosis. 251 
Potentially diabetogenic effects of LDL on islets. LDL tended to decrease maximal glucose-252 
stimulated insulin secretion from murine and human islets at clinically relevant concentrations. We 253 
hypothesize that LDL only affects the secretory machinery and not the production of insulin since no 254 
difference was observed in either total insulin content or insulin mRNA level between LDL treated 255 
and untreated islets. The LDL receptor appears to play a central role in mediating these adverse effects 256 
since LDL did not impair maximal insulin secretion from islets of LDLR -/- mice. In agreement with a 257 
limiting effect of the LDL receptor on β-cell function, it has been reported that patients with 258 
heterozygous LDL receptor deficiency are at reduced risk for developing diabetes mellitus (21, 22). 259 
Conversely the increased risk of diabetes mellitus observed in patients treated with lipophilic statins, 260 
which can enter β−cells, may be explained by statin-induced upregulation of the LDL receptor (23, 261 
24). Since the LDL receptor acts as an endocytic receptor we hypothesize that the impairment of 262 
maximal glucose-stimulated insulin secretion by LDL is mediated by a component of LDL which is 263 
internalized by the LDL receptor pathway. Possibly this component is cholesterol because impaired 264 
cholesterol homeostasis in islets for example of mice with a β-cell specific knock-out of the ATP-265 
binding cassette transporter A1 and hence disturbed cholesterol efflux was previously shown to 266 
contribute to islet dysfunction (9). Similar to our ex-vivo model, cholesterol accumulation in β-cells 267 
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led to impaired insulin secretion without affecting insulin production (7, 25). Conversely, lowering 268 
cholesterol levels in β-cells with methyl-β-cyclodextrin, which depletes membrane cholesterol, or with 269 
a statin, which inhibits de novo synthesis, was found to improve the secretory function of β-cells and 270 
increase insulin secretion (25). However, the mechanism by which cholesterol accumulation in β-cells 271 
interferes with glucose-stimulated insulin secretion remains to be further investigated. 272 
In parallel with impairing the maximal insulin secretion of β-cells, LDL also decreased the basal 273 
proliferation of mouse and human islet cells. This finding is in agreement with previous findings in 274 
βTC3 cells where elevated LDL concentrations decreased cell proliferation (6, 26). Moreover, in 275 
contrast to the inhibitory effect of LDL on insulin secretion, the anti-proliferative effect of LDL was 276 
not abolished in islets of LDLR -/- mice and hence appears to be independent of LDL uptake by the 277 
LDL receptor. This does not exclude that internalization of cholesterol or other LDL components 278 
interferes with β-cell proliferation since β-cells express several receptors which mediate the 279 
internalization of cholesterol with LDL, e.g. apoER2 (6). In addition scavenger receptors for modified 280 
LDL must be considered as candidates, although we took several measures to prevent lipoprotein 281 
modification during the experiments: anti-oxidants were added to the culture media and the LDL 282 
containing cell culture media were discarded and replaced with fresh lipoproteins every day during the 283 
culture period. Since the anti-proliferative effect of LDL was still observed under these conditions, we 284 
assume that native rather than oxidatively modified LDL is responsible for this anti-proliferative 285 
effect. 286 
In contrast to Roehrich et al (6, 8) but in agreement with Abderrahmani and collegues (6, 8) we did not 287 
observe any significant effect of native LDL on the survival of either mouse or human islet cells. 288 
However, Roehrich et al (6, 8) used higher concentrations of LDL than we did. Moreover, 289 
Abderrahmani and collegues (6, 8) found that oxidatively modified LDL induces apoptosis of β-cells. 290 
It may hence well be that in addition to the adverse effects on function and proliferation LDL has 291 
negative impact also on β-cell survival when it is modified or present at very high concentrations. 292 
Potentially anti-diabetogenic effects of HDL on islets. In the present study and in agreement with 293 
the data from Roehrich et al (6, 8), we found that HDL decreases basal human and mouse islet cells 294 
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apoptosis without influencing the function or the proliferation of these cells. Moreover, HDL protected 295 
islet cells from glucose and IL-1β induced apoptosis. These protective effects were specific for β-cells 296 
as indicated by our immunological colocalization experiments. The protective effects exerted by HDL 297 
suggest a modulating role for this particle on the survival of β-cells and hence in the pathogenesis of 298 
type 2 diabetes. 299 
Since HDL is a very heterogeneous class of lipoproteins that contains more than 50 bioactive proteins 300 
(27) and even more lipid species (28) we attempted to uncover the component of HDL affecting islet 301 
cell survival. Surprisingly, both the protein and lipid moieties of HDL were found to protect islet cells 302 
against glucose induced apoptosis. Notably, purified ApoA1, the main protein constituent of HDL, and 303 
S1P protected islet cells from IL-1β and glucose induced apoptosis. These results are in agreement 304 
with a previously published study where S1P protected a rat β-cell line against cytokines induced 305 
apoptosis (29). Interestingly, both ApoA1 and S1P were previously also found to exert anti-306 
inflammatory and anti-apoptotic effects on endothelial cells (30). In endothelial cells the antiapoptotic 307 
effect of S1P involves the phosphorylation of endothelial nitric oxide synthase (eNOS) which however 308 
is not expressed in β-cells. Rather the inducible nitric oxide synthase iNOS is expressed which is 309 
known to mediate the proapoptotic effects of glucose and cytokines (31). Interestingly exposure of 310 
mouse islets to HDL downregulated iNOS mRNA expression as well as downstream target of 311 
activated iNOS, namely Fas while the anti-apoptotic FLIP was up-regulated. 312 
Both S1P receptors and the HDL receptor SRB1 have been shown to mediate the anti-apoptotic effects 313 
of HDL on endothelial cells (32, 33) and to be expressed on β-cells (6, 34). The role of SRB1 in the 314 
mediation of the protection of islet cells against IL-1β induced apoptosis by HDL is not clear. Our data 315 
suggest that SRB1 is probably not involved in the inhibition of IL-1β induced apoptosis by HDL since 316 
the inhibitory effect of HDL was similar in islets from SRB1 -/- and wild type mice although only the 317 
effect in wild type islets was statistically significant. 318 
In conclusion and to the best of our knowledge, we showed for the first time that LDL and HDL 319 
influence the survival and function not only of transformed β-cell lines or primary murine β-cells but 320 
also of primary human islets. In addition we showed that the effects of LDL on insulin secretion and 321 
12 
 
β-cell proliferation are exerted by different pathways, namely dependently and independently, 322 
respectively of the LDL receptor. Finally we identified two components of HDL, ApoA1 and S1P, by 323 
which HDL protect β-cells from cytokine or glucose induced apoptosis. Together with data from other 324 
laboratories and epidemiological studies these findings point to the relevance of both lipoprotein 325 
classes for the pathogenesis of diabetes mellitus. The data provide a rationale for future studies to 326 
show that a good control of LDL and HDL plasma concentrations does not only prevent 327 
atherosclerosis as an important complication but also the onset and progression of type 2 diabetes. 328 
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FIGURE LEGENDS 453 
FIG.1. LDL decreases basal proliferation and function of mouse and human islet cells. Mouse 454 
islets (A, C, E, G, I) or human islets (B, D, F) were cultured on extracellular matrix-coated dishes for 2 455 
(I) or 4 (A – G) days at 11 mM (mouse) or 5 mM (human) glucose in the presence of increasing 456 
concentrations of LDL. A: BrdU positive mouse islet cells per islet (control = 3±0.3, n=3-9). B: Ki-67 457 
positive human islet cells per islet (control = 0.15±0.05, n=3-4). C: TUNEL positive mouse islet cells 458 
per islet (C: control = 0.7±0.3, n=6). D: TUNEL positive human islet cells per islet (control = 459 
0.34±0.1, n=3-4). E: Glucose-stimulated insulin secretion in mouse islets (n=5). F: Glucose-stimulated 460 
insulin secretion in human islets (n=5). G: Mouse islets were dispersed into single cells and cultured as 461 
single cells for 4 days on extracellular matrix-coated dishes in the absence (control) or presence of 462 
LDL (3.1 mM). BrdU positive mouse β-cells (control = 0.14±0.07, n=6). H: Picture of a representative 463 
mouse islet co-stained for BrdU (1) and DAPI (2). I: BrdU positive mouse islet cells per islet (control 464 
= 3.8±1.3, n=3). J: Picture of a representative mouse islet co-stained for TUNEL (1) and DAPI (2). 465 
Where * represents p<0.05 as tested by ANOVA followed by Bonferroni’s post-hoc test (A-D) or by 466 
Student’s t test (E-G). 467 
FIG.2. LDL decreased islet cell proliferation is independent of the LDL receptor. Mouse islets 468 
from LDLR +/+ (A, C) or LDLR -/- (B, D) mice were cultured for 4 days in 11 mM glucose on 469 
extracellular matrix-coated dishes in the absence (control) or presence of LDL (3.1 mM). A: BrdU 470 
positive cells per wild type islet in the absence (control) or presence of LDL (3.1 mM) (control = 471 
1.8±1, n=3). B: BrdU positive cells per LDLR -/- islet in the absence (control) or presence of LDL (3.1 472 
mM) (control = 1.4±0.5, n=3). C: Glucose-stimulated insulin secretion in wild type mouse islets in the 473 
absence (control) or presence of LDL (3.1 mM) (n=3). D: Glucose-stimulated insulin secretion in 474 
LDLR -/- mouse islets in the absence (control) or presence of LDL (3.1 mM) (n=3). E: % inhibition of 475 
stimulated insulin secretion (n=3). Where * represents p<0.05 as tested by Student’s t-test. 476 
FIG.3. HDL decreases basal apoptosis of mouse and human islet cells. Mouse and human islets 477 
were cultured on extracellular matrix-coated dishes for 4 days at 11 mM (mouse) or 5 mM (human) 478 
glucose in the presence of increasing concentrations HDL. A: BrdU positive mouse islet cells per islet 479 
(control = 5.1±1.2, n=5). B: Ki-67 positive human islet cells per islet (control = 0.07±0.03, n=7-12). 480 
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C: TUNEL positive mouse islet cells per islet (control = 1.7±0.7, n=5-17). D: TUNEL positive human 481 
islet cells per islet (control = 0.33±0.04, n=4-11). E: Glucose-stimulated insulin secretion in mouse 482 
islets (n=5). F: Glucose-stimulated insulin secretion in human islets (n=5). Where * represents p<0.05 483 
as tested by ANOVA followed by Bonferroni’s post-hoc test. 484 
FIG.4. HDL protects mouse β-cells from IL-1β induced apoptosis. Islets were cultured for 2 (C, D, 485 
E) or 4 (A, B) days on extracellular matrix-coated dishes. A: TUNEL positive human islet cells per 486 
islet after 4 days culture in 5 (control) or 33 mM glucose (Glc) in the absence (control) or presence of 487 
HDL (1 mM) (control = 0.1±0.05, n=4). B: TUNEL positive mouse islet cells per islet after 4 days 488 
culture in 11 (control) or 33 mM glucose (Glc) in the absence (control) or presence of HDL (0.8 mM) 489 
(control = 0.45±0.1, n=7). C: TUNEL positive mouse islet cells per islet after 2 days culture in 11 mM 490 
glucose in the absence (control) or presence of IL-1β (2 ng/ml) and in the absence (control) or 491 
presence of HDL (0.8 mM) (control = 0.46±0.1, n=16). D: TUNEL positive β-cells per islet after 2 492 
days culture in 11 mM glucose in the absence (control) or presence of IL-1β (2 ng/ml) and in the 493 
absence (control) or presence of HDL (0.8 mM) (control = 0.34±0.2, n=3). E: TUNEL positive non β-494 
cells per islet after 2 days culture in 11 mM glucose in the absence (control) or presence of IL-1β (2 495 
ng/ml) and in the absence (control) or presence of HDL (0.8 mM) (control = 0.47±0.2, n=3). F: 496 
Confocal microscope pictures of a representative islet co-stained for insulin (1), TUNEL (2) and Dapi 497 
(3). Pictures of the different stainings on planes XZ and the overlay (4, XZ and XY planes) are shown. 498 
Where * represents p<0.05 as tested by ANOVA followed by Bonferroni’s post-hoc test. 499 
FIG.5. HDL mediated β-cell protection against IL-1β induced apoptosis is independent of SRB1 500 
expression. ApoA1 and S1P mediate the protective effect of HDL on islet cell apoptosis. Islets 501 
were cultured for 2 (A, B, E, F, G) or 4 (C, D) days on extracellular matrix-coated dishes. A: TUNEL 502 
positive β-cells per wild type islet after 2 days culture in 11 mM glucose in the absence (control) or 503 
presence of IL-1β (2 ng/ml) and in the absence (control) or presence of HDL (0.8 mM) (control = 504 
0.34±0.13, n=4). B: TUNEL positive β-cells per SRB1 -/- islet after 2 days culture in 11 mM glucose 505 
in the absence (control) or presence of IL-1β (2 ng/ml) and in the absence (control) or presence of 506 
HDL (0.8 mM) (control = 0.5±0.2, n=3). C: TUNEL positive mouse islet cells per islet after 4 days 507 
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culture in 11 (control) or 33 mM glucose (Glc) in the absence (control) or presence of HDL protein 508 
moiety (pHDL, 20 μg/ml) (control = 0.31±0.1, n=4). D: TUNEL positive mouse islet cells per islet 509 
after 4 days culture in 11 (control) or 33 mM glucose (Glc) in the absence (control) or presence of 510 
ApoA1 (20 μg/ml) (control = 0.17±0.1, n=3). E: TUNEL positive mouse islet cells per islet after 2 511 
days culture in 11 mM glucose in the absence (control) or presence of IL-1β (2 ng/ml) and in the 512 
absence (control) or presence of ApoA1 (20 μg/ml) (control = 0.12±0.06, n=3) F: TUNEL positive 513 
mouse islet cells per islet after 2 days culture in 11 mM glucose in the absence (control) or presence of 514 
IL-1β (2 ng/ml) and in the absence (control) or presence of HDL lipid moiety (lHDL 0.8 mM) (control 515 
= 0.6±0.2, n=3). G: TUNEL positive mouse islet cells per islet after 2 days culture in 11 mM glucose 516 
in the absence (control) or presence of IL-1β (2 ng/ml) and in the absence (control) or presence of S1P 517 
(1 μM) (control = 1±0.3, n=3). Where * represents p<0.05 as tested by ANOVA followed by 518 
Bonferonni’s post-hoc test 519 
FIG.6. HDL down regulates Fas and iNOS and upregulates FLIP mRNA expression. Mouse 520 
islets were cultured for 2 or 4 days on extracellular matrix-coated dishes prior to RNA extraction. 521 
Semi-quantitative analysis of gene expression was performed with the TaqMan technology. A and B: 522 
iNOS mRNA expression after 2 days incubation in the absence (control) or presence of HDL (0.8 523 
mM) and with or without IL-1β (2 ng/ml) (A and B: n=5). C, D, E, F: Fas (C), FLIP (D), Bcl2 (E) and 524 
SOCS3 (F) mRNA expression after 4 days incubation in the absence (control) or presence of HDL 525 
(0.8 mM) (C: n=7; D: n=6; E: n=8; F: n=5).* represents p<0.05 as tested by Student’s t test. 526 
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